Summary
The broad application of recombinant adenoviruses to the development of vaccines and gene therapy vectors has encouraged the development of molecular assays for the facile quantitation of adenoviral particles and the assignment of their infectious potency. The Genome Quantitation Assay (GQA) and the QPCR-Based Potency Assay (QPA) developed for adenoviruses offer the attributes of precision, rapidity, and high throughput either performed manually or facilitated by simple automated liquid handling systems. These assay attributes allow for accelerated process development support and product characterization and release. The assays for adenovirus could offer the additional advantage in that their quantitation is based on viral replication independent of cytopathology permitting quantitation of serotypes that cause minimal cytopathic effect (CPE) in 293 cells and specificity that allows the components of multivalent vaccines to be discriminated and quantitated for release.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Reference
Rowe, W.P., Huebner, R.J., Gilmore, L.K., Parrott, R.H., and Ward T.G. (1953) Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Biol. Med. 84, 570–573.
Hilleman, M.R. and Werner, J.H. (1954) Recovery of new agents from patients with acute respiratory illness. Proc. Soc. Exp. Biol. Med. 85, 183–188.
Horwitz, M.S. (1996) Adenoviruses in Virology by Fileds, B.N., Knipe D.M., and Howley P.M. eds. Lippincott Williams & Wilkins Vol. 2, pp. 22149–22171.
Hilleman, M.R. (1958) Efficacy of and indications for use of adenovirus vaccine. Am. J. Public Health 48, 153–158.
Shiver, J.W., Fu, T.M., Chen, L., Casimiro, D.R., Davies, M.E., Evans, R.K., Zhang, Z.Q., Simon, A.J., Trigona, W.L., Dubey, S.A., Huang, L., Harris, V.A., Long, R.S., Liang, X., Handt, L., Schleif, W.A., Zhu, L., Freed, D.C., Persaud, N.V., Guan, L., Punt, K.S., Tang, A., Chen, M., Wilson, K.A., Collins, K.B., Heidecker, G.J., Fernandez, V.R., Perry, H.C., Joyce, J.G., Grimm, K.M., Cook, J.C., Keller, P.M., Kresock, D.S., Mach, H., Troutman, R.D., Isopi, L.A., Williams, D.M., Xu, Z., Bohannon, K.E., Volkin, D.B., Montefiori, D.C., Miura, A., Krivulka, G.R., Lifton, M.A., Kuroda, M.J., Schmitz, J.E., Letvin, N.L., Caulfield, M.J., Bett, A.J., Youil, R., Kaslow, D.C., Emini, E.A. (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331–335.
Shiver, J.W. and Emini, E.A. (2004) Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Ann. Rev. Med. 55, 355–372.
Engelhardt, J.F., Yang, Y., Stratford-Perricaudet, L.D., Allen, E.D., Kozarsky, K., Perricaudet, M., Yankaskas, J.R., and Wilson, J.M. (1993) Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses. Nat. Genet. 4, 27–34.
Zabner, J., Couture, L.A., Gregory, R.J., Graham, S.M., Smith, A.E., Welsh, M.J. (1993) Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis. Cell 75, 207–216.
Crystal, R.G., McElvaney, N.G., Rosenfeld, M.A., Chu, C.S., Mastrangeli, A., Hay, J.G., Brody, S.L., Jaffe, H.A., Eissa, N.T., and Danel, C. (1994) Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat. Genet. 8, 42–51.
Lemckert, A.A., Sumida, S.M., Holterman, L., Vogels, R., Truitt, DM., Lynch, D.M., Nanda, A., Ewald, B.A., Gorgone, D.A., Lifton, M.A., Goudsmit, J., Havenga, M.J., and Barouch, D.H. (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J. Virol. 79, 9694–9701.
Graham, F.L., Smiley, J., Russell, W.C., and Nairn, R. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59–74.
Fallaux, F.J., Bout, A., van der Velde, I., van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., van Ormondt, H., van der Eb, A.J., Valerio, D., and Hoeben, R.C. (1998) New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum. Gene Ther. 9, 1909–1917.
Maizel, J.V., White D.O., and Scharff, M.D. (1968) The polypeptides of adenovirus: evidence for multiple protein components in the virions and a comparison of types 2, 7A and 12. Virology 36, 115–125.
Sweeney, J.A. and Hennessey, J.P. (2002) Evaluation of accuracy and precision of adenovirus absorptivity at 260 nm under conditions of complete DNA disruption. Virology 295, 284–288.
Shabram, P.W., Giroux, D.D., Goudreau, A.M., Gregory, R.J., Horn, M.T., Huyghe, B.G., Liu, X., Nunnally, M.H., Sugarman, B.J., and Sutjipto, S. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther. 8, 453–465.
Ma, L., Bluyssen, H.A., De Raeymaeker, M., Laurysens, V., van der Beek, N., Pavliska, H., van Zonneveld, A.J., Tomme, P., and van Es, H.H. (2001) Rapid determination of adenoviral vector titers by quantitative real-time PCR. J. Virol. Methods 93, 181–188.
Wang, L., Wang, C.J., Tan, C.Y., Hsu, D., and Hennessey, J.P. Jr. (2006) A robust approach for the quantitation of viral concentration in an adenoviral vector-based human immunodeficiency virus vaccine by real-time quantitative polymerase chain reaction. Hum. Gene Ther. 17, 1–13.
Heid, C.A., Stevens, J., Livak, K.J., and Williams, P.J. (1996) Real time quantitative PCR. Genome Res. 6, 986–994.
Wang, F., Puddy, A.C., Mathis, B.C., Hager, A., Louis, A., McMackin J., Xu, J., Zhang, Y., Tan, C., Schofield, T.S., Wolf, J.J. and Lewis J.A. (2005) Using QPCR to assign infectious potencies to adenovirus based vaccines and vectors for gene therapy. Vaccine 23, 4500–4508.
Wigund, R. and Kumel, G. (1977) The kinetics of adenovirus infection and spread in cell cultures infected with low multiplicity. Arch. Virol. 54, 177–187.
Acknowledgments
The authors thank our colleagues who provided strong support throughout this work (alphabetically): Andrew Bett, Barry Buckland, Carrie Harper, Anthonise Louis, Jennifer McMackin, Allen Puddy, Volker Sandig, Timothy Schofield, Robert Sitrin, Charles Tan, Jenny Xu, and Yuhua Zhang.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Wang, F., Mathis, B.C., Montalvo, A., Wolf, J.J., Lewis, J.A. (2008). Quantifying the Titer and Quality of Adenovirus Stocks. In: Le Doux, J.M. (eds) Gene Therapy Protocols. Methods in Molecular Biology™, vol 434. Humana Press. https://doi.org/10.1007/978-1-60327-248-3_3
Download citation
DOI: https://doi.org/10.1007/978-1-60327-248-3_3
Publisher Name: Humana Press
Print ISBN: 978-1-60327-247-6
Online ISBN: 978-1-60327-248-3
eBook Packages: Springer Protocols